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Hepatocellular carcinoma is a highly heterogeneous disease both at the molecular and clinical levels. Intra-tumor morphological and genetic heterogeneity adds a new level of complexity in our understanding of liver carcinogenesis, and it is likely an important determinant of primary and secondary resistance to targeted therapies.
Research. (1) . To this purpose, they performed geographical sampling of 120 different regions in this set of tumors. They collected the different pathological features and performed immunostaining to assess the activation of WNT/β-catenin pathway (β-catenin, glutamine synthase), the presence of stem cells markers (CK7, EPCAM and CD44), as well as CD34 and AFP expression. They also performed sequencing of TP53 and CTNNB1 (coding for β-catenin), two of the most frequently mutated genes in HCC.
Morphological heterogeneity was observed in 87% of the cases and heterogeneity at the immunohistochemical (IHC) and morphological level in 61% of the cases. Strikingly, genetic intra-tumor heterogeneity was noted in 22% of the cases and was systematically associated with heterogeneity at both the pathological and IHC level. This suggested that, at least in these cases, genotype and phenotype were strongly correlated. Authors also showed how different CTNNB1 mutations could be observed in different regions of the same tumor. As predicted, intra-tumor heterogeneity was more frequent in larger tumors suggesting that heterogeneity increases as tumor progresses. The authors postulate that genetic and phenotypic intra-tumor heterogeneity is frequent in HCC and questioned the use of single-biopsy to identify prognostic and predictive biomarkers.
Phenotypic heterogeneity has been widely described by pathologists. However, our understanding of genetic intra-tumor heterogeneity has been limited until recently due to our incomplete structural knowledge of the cancer genome, and to the lack of technology sensitive enough to easily detect tumor sub-clones. Luckily, the introduction of next-generation sequencing enabled scientist to draw the genetic landscape of the most frequent tumors. Moreover, it has allowed analytic refinements to identify low frequencies mutations and consequently to assess sub-clonality. As other cancers, HCC is a disease of the genome, where somatic mutations (Fig. 1) . Genetic intra-tumor heterogeneity has been barely evaluated in HCC and despite the relevant information provided by Friemel et al., the study leaves some unanswered questions. For example, they only focused on CTNNB1 and TP53 mutations but there are other somatic mutations identify using deep sequencing targeting ARID1A, ARID2, NFE2L2, KEAP1, RPS6KA3, MLL2, MLL3 or MLL4 for which there is no data regarding intra-tumor distribution (6) . Moreover, we recently identify TERT promoter mutations as the most frequent somatic genetic defect in HCC, with an overall frequency of 60% (7). TERT promoter is also recurrently mutated in precancerous nodules. It is one of the earliest genetic alterations involved in malignant transformation in HCC and could be considered as a tumor "gatekeeper". We could speculate that TERT promoter mutations are present in the common ancestor cell, being transmitted to its progeny and hence present in most tumor cells. As noted by the authors, further studies are still needed to decipher HCC intra-tumor genetic heterogeneity using unbiased approaches such as whole-exome or whole-genome sequencing, preferable by ultra-deep sequencing (2,3). Another issue raised by Friemel et al. is the reliability of molecular classification and genetic analysis using one single sample of resected tumors or using a single tumor biopsy. They suggest that tumor heterogeneity could challenge the use of molecular classification and development of biomarker driven targeted therapies in the field of HCC.
However, such assumption needs to be balanced considering the available data. Several molecular prognostic signatures derived from the tumor have been validated in large and independent studies despite tumor heterogeneity (8, 9) . Also, all biomarker-based molecular therapies approved in solid malignancies are based on traditional genetic analysis of the tumor, that didn't account for genetic heterogeneity. Some examples are vemurafenib for BRAF V600E mutated melanoma, cetuximab for wild type RAS colorectal cancer or crizotinib for ALK translocated non-small cell lung cancer. The fact that independent tumor clones ("multicentric carcinogenesis") can arise on cirrhotic livers adds an additional layer of complexity (Fig. 1) . New data are required to delineate inter-tumor molecular heterogeneity and accurately distinguish between intrahepatic metastasis and multicentric carcinogenesis (i.e., de novo tumor) on a cirrhotic background. Until we understand the nature, mechanisms and consequences of this molecular diversity, it will be difficult to evaluate its impact in clinical practice. Accurate assessment of intra-and inter-tumor heterogeneity will be also pivotal to understand primary or secondary resistance to targeted therapies. Coupled with the analysis of the tumor genome, circulating tumor DNA will be an interesting tool to monitor tumor heterogeneity longitudinally and easily in clinical practice (10) .
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